← Leaderboards
Richard G Gorlick
Sloan-Kettering Institute For Cancer Res
$6,335,543
Attributed
$6,335,543
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,160,163 · 6
By mechanism
U01$3,599,631 · 1
P50$2,629,697 · 3
P01$1,049,011 · 1
R01$881,824 · 1
Top collaborators
- Phillip Andrew Futreal1 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Ronald P Dematteo$17,312,014
- Joseph Rocco Bertino$26,398,552
- Tanya M Trippett$245,646
- William K Kelly$669,280
- Elliot J Coups$3,232,682
Others in their field
Top investigators on “Osteosarcoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$59,413,213
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Timothy J. Triche · University Of Southern California$14,547,053
- Dean W Felsher · Stanford University$11,822,756
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Peter J Houghton · University Of Texas Hlth Science Center$8,450,965
Research focus
OsteosarcomaTumorPreclinical TestingNew AgentsSamplingChildXenograft ProcedureClinical TrialsCell LineMolecularAdolescent And Young AdultTargeted TreatmentResponsePharmaceutical PreparationsChemotherapyChildhoodPediatric Oncology GroupLeadResourcesYoung AdultMolecular MarkerFutureLaboratoriesIncidence
Grant awards (27)
MD Anderson Sarcoma SPORE$1,824,620
P50 · FY2025 · CA · contact PI
Project 3: Development of Novel Antibody Drug Conjugates for the Treatment of Osteosarcoma$477,912
P50 · FY2025 · CA · contact PI
Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models$405,000
U01 · FY2025 · CA · contact PI
Administrative Core$327,165
P50 · FY2025 · CA · contact PI
Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models$402,869
U01 · FY2024 · CA · contact PI
Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models$394,769
U01 · FY2023 · CA · contact PI
Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models$396,900
U01 · FY2022 · CA · contact PI
Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models$405,000
U01 · FY2021 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$160,233
U01 · FY2021 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$177,926
U01 · FY2020 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$351,458
U01 · FY2019 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$136,071
U01 · FY2018 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$249,200
U01 · FY2017 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$260,103
U01 · FY2016 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$242,719
U01 · FY2015 · CA · contact PI
Osteosarcoma: Patient Derived Xenograft Preclinical Testing$17,383
U01 · FY2015 · CA · contact PI
Core E$268,972
P01 · FY2009 · CA · contact PI
Core E$261,877
P01 · FY2008 · CA · contact PI
Core E$260,203
P01 · FY2007 · CA · contact PI
Antifolate Resistance in Osteosarcoma$149,529
R01 · FY2007 · CA · contact PI
Antifolate Resistance in Osteosarcoma$153,995
R01 · FY2006 · CA · contact PI
Core E$142,275
P01 · FY2006 · CA · contact PI
Antifolate Resistance in Osteosarcoma$156,750
R01 · FY2005 · CA
Core E$115,684
P01 · FY2005 · CA
Antifolate Resistance in Osteosarcoma$155,800
R01 · FY2004 · CA
ANTIFOLATE RESISTANCE OSTEOSARCOMA$134,839
R01 · FY2001 · CA
ANTIFOLATE RESISTANCE OSTEOSARCOMA$130,911
R01 · FY2000 · CA